SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-064516
Filing Date
2023-08-08
Accepted
2023-08-08 16:01:17
Documents
14
Period of Report
2023-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea183062-8k_inmune.htm   iXBRL 8-K 24256
2 PRESS RELEASE DATED AUGUST 7, 2023 ea183062ex99-1_inmune.htm EX-99.1 98276
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3251
  Complete submission text file 0001213900-23-064516.txt   316379

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20230807.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20230807_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20230807_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea183062-8k_inmune_htm.xml XML 3409
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 231151049
SIC: 2836 Biological Products, (No Diagnostic Substances)